Liquid chromatographic-electrospray mass spectrometric determination of 1-methyl-4-phenylpyridine (MPP+) in discrete regions of murine brain

Toxicology Mechanisms and Methods

Volumn 21, Issue 3, 2011, Pages 171-182

  Lehner, Andreas ^a,c   Johnson, Margaret ^a   Simkins, Tyrell ^b   Janis, Kelly ^b   Lookingland, Keith ^b   Goudreau, John ^a   Rumbeiha, Wilson ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Diagnostic Center for Population and Animal Health   (United States)

Author keywords

dopamine; HPLC; LC MS MS; MPP+; MPTP

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADRENALIN; CITRIC ACID; DOPAMINE; METHANOL; NORADRENALIN; PHOSPHATE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CHEMICAL ANALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATIONAL STUDY; DOPAMINE BRAIN LEVEL; ELECTROCHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; FRAGMENTATION REACTION; FREEZING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MICRODISSECTION; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; BRAIN; CHROMATOGRAPHY, LIQUID; FEMALE; HERBICIDES; MICE; MICE, INBRED C57BL; NEURONS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

MURINAE; MUS;

EID: 79951893475     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2010.538753     Document Type: Article

References (39)

1. Behrouz B, Drolet RE, Zayed ZA, Lookingland KJ, Goudreau JL. 2007. Unique response to mitochondrial Complex I inhibition in tuberoinfundibular dopamine neurons may impart resistance to toxic insult. Neuroscience 147:592-598.
2. Boismenu D, Mamer O, Ste-Marie L, Vachon L, Montgomery J. 1996. In vivo hydroxylation of the neurotoxin, 1-methyl-4-phenylpyridinium, and the effect of monoamine oxidase inhibitors: electrospray-MS analysis of intrastriatal microdialyzates. J Mass Spectrom 31:1101-1108.
3. Cox FJ, Johnston MV, Dasgupta A. 2003. Characterization and relative ionization efficiencies of end-functionalized polystyrenes by matrix-assisted laser desorption/ionization mass spectrometry. J Am Soc Mass Spectrom 14:648-657.
4. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39:889-909.
5. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ. 1979. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1:249-254.
6. Di Monte DA, Langston JW. 2000. MPTP and analogs. In: Spencer PS, Schaumburg HS, editors. Experimental and clinical neurology. 2nd ed. New York: Oxford University Press. pp 812-818.
7. Filipov NM, Norwood AB, Sistrunk SC. 2009. Strain-specific sensitivity to MPTP of C57BL/6 and BALB/c mice is age dependent. Neuroreport 20:713-717.
8. Franklin KBJ, Paxinos G. 1996. The mouse brain in stereotaxic coordinates. New York: Academic Press.
9. Fuller RW, Hemrick-Luecke SK, Perry KW. 1989. Tissue concentrations of MPTP and MPP+ in relation to catecholamine depletion after the oral or subcutaneous administration of MPTP to mice. Life Sci 45:2077-2083.
10. Gessner W, Brossi A, Shen R, Abell CW. 1985. Further insight into the mode of action of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). FEBS Lett 183:345-348.
11. Gessner W, Brossi A, Shen R, Fritz RR, Abell CW. 1984. Conversion of 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its 5-methyl analog into pyridinium salts. Helvetica Chimica Acta 67:2029-2272.
12. Giovanni A, Sieber B, Heikkila RE, Sonsalla PK. 1991. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methly-4-phenyl-1,2,3,6- tetrathydropyridine administration to several strains of mice. J Pharmacol Exp Therapeut 257:691-697.
13. Giuseppe B, Busceti CL, Pontarelli F, Biagioni F, Fornai F, Paparelli A, Bruno V, Ruggieri S, Nicoletti F. 2003. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1- methyl- 4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology 45:155-166.
14. Gruetzmacher HF. 1992. Unimolecular reaction mechanisms: the role of reactive intermediates. Int J Mass Spectrom Ion Processes 118-119:825-855
15. Guo Y. 2005. Analysis of quaternary amine compounds by hydrophilic interaction chromatography/mass spectrometry (HILIC/MS). J Liq Chromatogr R T 28:497-512.
16. Hammock BD, Beale AM, Work T, Gee SJ, Gunther R, Higgins RJ, Shinka T, Castagnoli, N, Jr. 1989. A sheep model for MPTP induced Parkinson-like symptoms. Life Sci 45:1601-1608.
17. Hows ME, Ashmeade TE, Billinton A, Perren MJ, Austin AA., Virley DJ, Organ AJ, Shah AJ. 2004. High-performance liquid chromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates. J Neurosci Methods 137:221-226.
18. Ishii A, Watanabe-Suzuki K, Seno H, Suzuki O, Katsumata Y. 2002. Application of gas chromatography-surface ionization organic mass spectrometry to forensic toxicology. J Chromatogr B Analyt Technol Biomed Life Sci 776:3-14.
19. Jackson-Lewis V, Smeyne RJ. 2005. From man to mouse: The MPTP model of Parkinson disease. In: LeDoux M, editor. Animal models of movement disorders. New York: Elsevier academic press. pp 149-160.
20. Langston JW, Ballard P, Tetrud JW, Irwin I. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980.
21. Lee XP, Kumazawa T, Fujishiro M, Hasegawa C, Arinobu T, Seno H, Ishii A, Sato K. 2004. Determination of paraquat and diquat in human body fluids by high-performance liquid chromatography/tandem mass spectrometry. J Mass Spectrom 39:1147-1152.
22. Lindley SE, Gunnet JW, Lookingland KJ, Moore KE. 1990. 3,4- Dihydroxyphenylacetic acid concentrations in the intermediate lobe and neural lobe of the posterior pituitary gland as an index of tuberohypophysial dopaminergic neuronal activity. Brain Res 506:133-138.
23. Lowry OH, Rosebrough NJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
24. Mabic S, Castagnoli N, Jr. 1998. Studies on the electron-impact-induced fragmentation of 1,4-disubstituted-1,2,3,6-tetrahydropyridines. J Mass Spectrom Soc Jpn 46:17-24.
25. McLafferty FW, Turecek F. 1993. Interpretation of mass spectra. 4th ed. Sausalito, CA: University Science Books. pp 69-70, 349.
26. Miller JC, Miller JN. 2000. Statistics and chemometrics for analytical chemistry. 4th ed. New York: Prentice Hall.
27. Nakamura S, Akiguchi I, Kimura J. 1995. Topographic distributions of monoamine oxidase-B-containing neurons in the mouse striatum. Neurosci Lett 184:29-31.
28. Ogunrombi MO, Malan SF, Blanche GT, Castagnoli K, Castagnoli N, Bergh JJ, Petzer JP. 2007. Neurotoxicity studies with the monamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline. Life Sci 81:458-467.
29. Palkovits M. 1973. Isolated removal of hypothalamic or other brain nuclei of the rat. Brain Res 59:449-450.
30. Palkovits M. 1983. Microdissection of brain areas by the punch technique. In: Ceullo A, editor. Brain microdissection techniques. New York: Wiley Interscience.
31. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, Akram M. 2001. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76:1265-1274.
32. Salach JI, Singer TP, Castagnoli N, Jr, Trevor A. 1984. Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochem Biophys Res Commun 125:831-835.
33. Sharma RK, Chan WG, Seeman JI, Hajaligol MR. 2003. Formation of low molecular weight heterocycles and polycyclic aromatic compounds (PACs) in the pyrolysis of alpha-amino acids. J Anal Appl Pyrol 66:97-121.
34. Swartz ME, Krull IS. 1997. Analytical method development and validation. New York: Marcel Dekker, Inc. pp 53-71.
35. Takada M, Li ZK, Hattoir T. 1990. Astroglial ablation prevents MPTP-induced nigrostriatal neuronal death. Brain Res 509:55-61.
36. Vaglini F, Fascetti F. 1996. Striatal MPP+ levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice. Neurodegeneration 5:129-136.
37. Van Eenoo P, Delbeke FT. 2004. Criteria in chromatography and mass spectrometry? a comparison between regulations in the field of residue and doping analysis. Chromatographia 59 (Suppl 1):S39-S44.
38. Winnik B, Barr DB, Thiruchelvam M, Montesanno MA, Richfield EK, Buckley B. 2009. Quantification of paraquat, MPTP, and MPP+ in brain tissue using microwave-assisted solvent extraction (MASE) and high- performance liquid chromatography-mass spectrometry. Anal Bioanal Chem 395:195-201.
39. Zhang MY, Kagan N, Sung ML, Zaleska MM, Monaghan M. 2008. Sensitive and selective liquid chromatography/tandem mass spectrometry methods for quantitative analysis of 1-methyl-4-phenyl pyridinium (MPP+) in mouse striatal tissue. J Chromatogr B Analyt Technol Biomed Life Sci 874:51-56.